Table 2.
Changes in laboratory findings at baseline and after 24 weeks of SGLT2i treatment in patients with NAFLD and type 2 diabetes mellitus
| Parameter | Baseline | Week 24 | p value |
|---|---|---|---|
| HbA1c (%) | 6.5 (6.3–7.7) | 5.9 (5.4–6.8) | 0.003 |
| FPG (mg/dL) | 132 (127–185) | 112 (89–144) | < 0.001 |
| Fasting insulin (μU/mL) | 18.5 (5–83.9) | 11.8 (1.6–21.0) | < 0.001 |
| HOMA-IR | 6.3 (2.0–27.3) | 3.2 (0.4–6.2) | < 0.001 |
| Platelet count (× 104/μL) | 20.9 (12.6–38.3) | 20.5 (12.7–33.1) | 0.298 |
| AST (IU/L) | 30 (15–83) | 21 (10-63) | 0.007 |
| ALT (IU/L) | 48 (14–118) | 27 (12–96) | 0.005 |
| GGT (IU/L) | 42 (22–124) | 28 (12–87) | 0.001 |
| Ferritin (ng/dL) | 130 (9–362) | 77 (5–292) | 0.002 |
| FIB-4 index | 1.42 (0.54–4.30) | 1.28 (0.53–3.14) | 0.163 |
| APRI | 0.43 (0.24–2.05) | 0.35 (0.14–1.44) | 0.031 |
| Creatinine (mg/dL) | 0.76 (0.55–1.17) | 0.82 (0.60–1.11) | 0.023 |
| BUN (mg/dL) | 13 (9–20) | 15 (8–21) | 0.082 |
| eGFR (mL/min/1.73 m2) | 66 (49–86) | 64 (49–81) | 0.108 |
| Uric acid (mg/dL) | 5.7 (2.9–8.1) | 4.9 (2.7–8.0) | 0.016 |
| TG (mg/dL) | 154 (70–300) | 119 (57–224) | 0.039 |
| Total-C (mg/dL) | 190 (147–234) | 185 (145–228) | 0.733 |
| LDL-C (mg/dL) | 122 (85–149) | 112 (86–151) | 0.776 |
| HDL-C (mg/dL) | 47 (34–85) | 49 (42–80) | 0.14 |
| TG/HDL-C ratio | 3.0 (1.1–7.5) | 2.2 (0.8–5.3) | 0.015 |
Values are presented as median (range)
ALT alanine aminotransferase, APRI AST to platelet ratio index, AST aspartate aminotransferase, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, FIB-4 Fibrosis-4, FPG fasting plasma glucose, GGT γ-glutamyl transferase, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostasis model assessment-insulin resistance, LDL-C low-density lipoprotein cholesterol, TG triglyceride, Total-C total cholesterol